Research: THOMPSON and COLLEAGUES,

Listed in Issue 232

Abstract

THOMPSON and COLLEAGUES, Cancer Therapy and Research Center, University of Texas Health Science Center at  San Antonio, Mail Code 8026, 7979 Wurzbach, Suite 627, Zeller Building, San Antonio, TX 78229, USA review clinical and preclinical evidence for dietary and pharmacological prevention of prostate cancer and discuss future prevention direction.

Background

The high global incidence of prostate cancer has led to a focus on chemoprevention strategies to reduce the public health impact of the disease.

Methodology

Early studies indicating that selenium and vitamin E might protect against prostate cancer encouraged large-scale studies that produced mixed clinical results.

Results

Next-generation prostate cancer prevention trials validated the impact of 5α-reductase inhibitors in hormone-responsive prostate cancer, and these results were confirmed in follow-up studies. Other interventions on the horizon, involving both dietary and pharmacological agents, hold some promise but require further investigation to validate their efficacy.

Conclusion

In this Review, we discuss the clinical and preclinical evidence for dietary and pharmacological prevention of prostate cancer and give an overview of future opportunities for chemoprevention.

References

Thompson IM Jr, Cabang AB, Wargovich MJ. Future directions in the prevention of prostate cancer. Nat Rev Clin Oncol 11(1):49-60. doi: 10.1038/nrclinonc.2013.211. Epub Nov 26 2013.  Jan 2014.

ICAN 2024 Skyscraper

Scientific and Medical Network 2

Cycle Around the World for Charity 2023

Climb Mount Kilimanjaro Charity 2023

top of the page